Investor Relations
Corporate Profile
Monte Rosa Therapeutics is a clinical stage biotechnology company developing novel molecular glue degrader (MGD) medicines for patients living with serious diseases such as oncology, autoimmune and inflammatory diseases. MGDs are small molecule protein degraders designed to employ the body’s natural mechanisms to selectively eliminate therapeutically relevant proteins. The company’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) platform enables it to rapidly identify protein targets and design highly selective degraders by combining diverse libraries of proprietary MGDs with in-house proteomics, structural biology, AI/machine learning, and computational chemistry capabilities. Monte Rosa is headquartered in Boston, Mass., with research operations in both Boston and Basel, Switzerland.
Recent Updates
3.17.2026
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Read More
3.16.2026
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Read More
2.24.2026
Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)
Read More
ASCO Genitourinary Cancers Symposium Presentation
view pdf
Keystone Symposia – MRT-6160, a highly selective and first-in-class VAV1-directed molecular glue degrader, demonstrates activity in multiple immune-mediated disease models
view pdf
Nature Structural & Molecular Biology – Cereblon induces G3BP2 neosubstrate degradation using molecular surface mimicry